Registry update — unassessed
Treatment of Choroidal Subretinal Neovascularization With Agents Directed Against the Immune Response
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
RCTNotable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Nov 29, 2016 · Discovered: Sep 19, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The abstract does not report the study outcomes, so whether any treatment prevented neovascularization or improved vision cannot be determined from this text
- The sample size and participant completion rates are not reported, limiting assessment of statistical power and internal validity
- No effect sizes or statistical significance values are provided for any treatment comparison
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 6 months
- Population
- Participants 55 years of age and older with age-related macular degeneration (AMD) and drusen larger than 63 μm. Vision in the study eye was between 20/20 and 20/400.
- Primary outcome
- Prevention of growth of new blood vessels in the eye (choroidal subretinal neovascularization) in participants with age-related macular degeneration.
- Effect size
- —
- Significance
- Not reported
- Journal
- National Eye Institute (NEI)
- Published
- Nov 29, 2016
Sources
Primary source
- National Eye Institute (NEI) ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
Participants were randomly assigned to one of three treatments - infliximab, sirolimus, or daclizumab - or to observation only.
This study examined whether the anti-inflammatory medicines infliximab, sirolimus or daclizumab, when given with a participant's current therapies, would prevent the growth of new blood vessels in the eye in participants with age-related macular degeneration (AMD).
Participants 55 years of age and older with AMD and drusen larger than 63um may be eligible for this study.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.